Dr. Qingzhou Ji is a Principal Scientist at MilliporeSigma. He currently leads an R&D team focused on improving the genome & epigenome editing technologies, primarily the CRISPR platform. He joined Sigma-Aldrich in 2010, focusing on the areas of gene regulation and epigenetics. Qingzhou obtained his PhD in Biochemistry and Molecular Biology from Peking University. Prior to joining Sigma-Aldrich, He was a postdoctoral fellow at The Howard Hughes Medical Institute and Albert Einstein College of Medicine, where he had worked in the areas of cell biology, molecular biology, cancer research and immunology.